CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S.
Hosted on MSN6d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII ...
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...
A nasal spray derived from ketamine gets federal clearance to help some people treat depression. The Federal Drug Administration approved "Spravato" from Johnson and Johnson, to be used by people ...
ScienceAlert on MSN7d
FDA-Approved Nasal Spray For Depression Is First Of Its KindA ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback